SBI Funds Management Limited made its stock market debut on Tuesday, July 21, 2026, listing at a premium on both the BSE and NSE. The stock opened at ₹610 on the BSE, reflecting a 6.27% premium over its IPO issue price of ₹574 per share. On the NSE, it debuted at ₹613.30, representing a 6.85% premium to the issue price.
The ₹9,812.91 crore SBI Funds Management IPO was open for subscription from July 14 to July 16, 2026. The public issue witnessed robust investor interest and was subscribed 41.66 times by the close of the subscription period.
[July 16, 2026, 7:00 PM]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
140.11x |
|
Non-Institutional Investors (NIIs) |
22.51x |
|
Retail Individual Investors (RIIs) |
3.60x |
|
Employees |
4.65x |
|
Shareholders |
9.52x |
|
Total |
41.66x |
Established in 1992, SBI Funds Management Limited is the asset management company (AMC) of SBI Mutual Fund, one of the largest mutual fund houses in India. The company operates as a joint venture between State Bank of India (SBI) and Amundi Asset Management, offering a diverse range of investment solutions, including mutual funds, portfolio management services (PMS), alternative investment funds (AIFs), specialised investment funds (SIFs), and investment advisory services.
As of December 31, 2025, SBI Funds Management oversaw a quarterly average assets under management (QAAUM) of ₹29.04 lakh crore and served over 16.05 million investors. The company held an estimated 15.5% share of the Indian mutual fund industry's AUM and leveraged a wide distribution network comprising branch offices, financial intermediaries, and digital investment platforms across the country.
|
Particulars |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
FY23 (in ₹ crore) |
|
Revenue from operations |
3,597.76 |
2,690.56 |
2,161.59 |
|
EBITDA |
3,412.94 |
2,718.82 |
1,810.41 |
|
Profit After Tax |
2,540.15 |
2,072.79 |
1,339.71 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.